接受化疗的非胰腺癌性胃肠道癌症患者门诊初级血栓预防随机对照试验的荟萃分析。
Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with nonpancreatic gastrointestinal cancers receiving chemotherapy.
作者信息
Htut Thura Win, Thein Kyaw Zin, Quick Donald Paul, Oo Thein Hlaing
机构信息
Department of Hematology, Aberdeen Royal Infirmary, Aberdeen, UK.
Department of Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
出版信息
Proc (Bayl Univ Med Cent). 2021 Sep 16;35(1):51-55. doi: 10.1080/08998280.2021.1973340. eCollection 2022.
Primary ambulatory thromboprophylaxis (PATP) in patients with solid malignancies is not routinely indicated. We performed a meta-analysis of randomized controlled trials (RCTs) to determine the benefit and risk of PATP in patients with nonpancreatic gastrointestinal cancers receiving chemotherapy. RCTs with venous thromboembolism (VTE) reduction as primary or secondary endpoints were included. A total of 1932 patients from subgroups of 3 RCTs were eligible. The VTE incidence was 1.26% and 2.55% in PATP and control arms, respectively (risk ratio 0.49; confidence interval 0.25 to 0.96; = 0.04), with a number needed to treat of 78 to prevent one VTE event. In gastric and gastroesophageal junction cancer patients, the VTE incidence was 1.37% and 3.40% in PATP and control arms, respectively (risk ratio 0.40; confidence interval 0.13 to 1.24; = 0.11). PATP should not be recommended in patients with nonpancreatic gastrointestinal cancers on chemotherapy.
实体恶性肿瘤患者的初级门诊血栓预防（PATP）通常并不适用。我们对随机对照试验（RCT）进行了荟萃分析，以确定PATP在接受化疗的非胰腺癌性胃肠道癌症患者中的益处和风险。纳入了以静脉血栓栓塞（VTE）减少为主要或次要终点的RCT。来自3项RCT亚组的总共1932名患者符合条件。PATP组和对照组的VTE发生率分别为1.26%和2.55%（风险比0.49；置信区间0.25至0.96；P = 0.04），预防1例VTE事件的需治疗人数为78。在胃癌和胃食管交界癌患者中，PATP组和对照组的VTE发生率分别为1.37%和3.40%（风险比0.40；置信区间0.13至1.24；P = 0.11）。对于接受化疗的非胰腺癌性胃肠道癌症患者，不应推荐使用PATP。
Zotero 插件